10-Q Filing

STREAMEX CORP. CIK: 1530766 Q3 2020

Filing Information

Form Type	10-Q
Accession Number	`0001185185-20-001502`
Period End Date	20200930
Filing Date	20201105
Fiscal Year	2020
Fiscal Period	Q3
XBRL Instance	biosig20200930_10q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 74 Income Statement 64 Cash Flow Statement 76 Stockholders Equity 59

Balance Sheet 74 line items

Line Item	Tag	Value	Unit	Period
Cash	`Cash`	$12.11M	USD	Point-in-time
Cash	`Cash`	$32.75M	USD	Point-in-time
Inventory	`InventoryNet`	$806.41K	USD	Point-in-time
Inventory	`InventoryNet`	$577.69K	USD	Point-in-time
Prepaid expenses and vendor deposits	`PrepaidExpenseCurrent`	$338.11K	USD	Point-in-time
Prepaid expenses and vendor deposits	`PrepaidExpenseCurrent`	$141.22K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$33.89M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$12.83M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$180.37K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$187.67K	USD	Point-in-time
Right-to-use assets, net	`OperatingLeaseRightOfUseAsset`	$409.98K	USD	Point-in-time
Right-to-use assets, net	`OperatingLeaseRightOfUseAsset`	$714.34K	USD	Point-in-time
Patents, net	`FiniteLivedIntangibleAssetsNet`	$364.54K	USD	Point-in-time
Patents, net	`FiniteLivedIntangibleAssetsNet`	$350.28K	USD	Point-in-time
Accounts payable and accrued expenses, related parties (in Dollars)	`AccountsPayableRelatedPartiesCurrent`	$154.50K	USD	Point-in-time
Accounts payable and accrued expenses, related parties (in Dollars)	`AccountsPayableRelatedPartiesCurrent`	$39.67K	USD	Point-in-time
Trademarks	`IndefiniteLivedTrademarks`	$1.12K	USD	Point-in-time
Trademarks	`IndefiniteLivedTrademarks`	$1.12K	USD	Point-in-time
Prepaid expenses, long term	`PrepaidExpenseNoncurrent`	$9.74K	USD	Point-in-time
Prepaid expenses, long term	`PrepaidExpenseNoncurrent`	$27.41K	USD	Point-in-time
Deposits	`DepositsAssetsNoncurrent`	$101.84K	USD	Point-in-time
Deposits	`DepositsAssetsNoncurrent`	$101.84K	USD	Point-in-time
Total assets	`Assets`	$34.95M	USD	Point-in-time
Total assets	`Assets`	$14.22M	USD	Point-in-time
Preferred stock, par value (in Dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value (in Dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value (in Dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	1.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	1.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	1.00M	shares	Point-in-time
Common stock, par value (in Dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in Dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Accounts payable and accrued expenses, including $154,500 and $39,674 to related parties as of September 30, 2020 and December 31, 2019, respectively	`AccountsPayableAndAccruedLiabilitiesCurrent`	$4.49M	USD	Point-in-time
Accounts payable and accrued expenses, including $154,500 and $39,674 to related parties as of September 30, 2020 and December 31, 2019, respectively	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.49M	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$128.48K	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$69.83K	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	30.12M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	23.32M	shares	Point-in-time
Lease liability, short term	`OperatingLeaseLiabilityCurrent`	$412.29K	USD	Point-in-time
Lease liability, short term	`OperatingLeaseLiabilityCurrent`	$396.31K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	23.32M	shares	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$4.96M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.03M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	30.12M	shares	Point-in-time
Lease liability, long term	`OperatingLeaseLiabilityNoncurrent`	$22.36K	USD	Point-in-time
Lease liability, long term	`OperatingLeaseLiabilityNoncurrent`	$311.13K	USD	Point-in-time
Total debt	`LiabilitiesNoncurrent`	$2.34M	USD	Point-in-time
Total debt	`LiabilitiesNoncurrent`	$4.98M	USD	Point-in-time
Commitments and contingencies (Note 11)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 11)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred Stock	`TemporaryEquityCarryingAmountAttributableToParent`	$215.00K	USD	Point-in-time
Preferred Stock	`TemporaryEquityCarryingAmountAttributableToParent`	$105.00K	USD	Point-in-time
Preferred stock	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $0.001 par value, authorized 200,000,000 shares, 30,118,196 and 23,323,087 issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	`CommonStockValue`	$23.32K	USD	Point-in-time
Common stock, $0.001 par value, authorized 200,000,000 shares, 30,118,196 and 23,323,087 issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	`CommonStockValue`	$30.12K	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$175.23M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$115.91M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-104.79M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-146.71M	USD	Point-in-time
Total stockholders' equity attributable to BioSig Technologies, Inc.	`StockholdersEquity`	$11.15M	USD	Point-in-time
Total stockholders' equity attributable to BioSig Technologies, Inc.	`StockholdersEquity`	$28.55M	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$1.32M	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$514.83K	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.32M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$12.42M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$36.01M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$9.97M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$29.87M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.66M	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$34.95M	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$14.22M	USD	Point-in-time

Income Statement 64 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$4.95M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$4.91M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$15.56M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$1.64M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$14.38M	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$32.63M	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$8.17M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$3.84M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$36.42K	USD	3 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$18.51K	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$67.09K	USD	3 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$23.87K	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$48.25M	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$19.37M	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$13.10M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$5.50M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-48.25M	USD	3 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-13.10M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-5.50M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-19.37M	USD	3 Qtrs
Interest income, net	`InterestIncomeExpenseNet`	$1.74K	USD	1 Quarter
Interest income, net	`InterestIncomeExpenseNet`	$44.77K	USD	3 Qtrs
Interest income, net	`InterestIncomeExpenseNet`	$84.62K	USD	3 Qtrs
Interest income, net	`InterestIncomeExpenseNet`	$39.35K	USD	1 Quarter
Loss on foreign currency translation	`GainLossOnDispositionOfAssets1`	$-1.16K	USD	3 Qtrs
Loss on foreign currency translation	`GainLossOnDispositionOfAssets1`	-	USD	3 Qtrs
Loss on foreign currency translation	`GainLossOnDispositionOfAssets1`	-	USD	1 Quarter
Loss on foreign currency translation	`GainLossOnDispositionOfAssets1`	-	USD	1 Quarter
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-13.10M	USD	1 Quarter
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-5.46M	USD	1 Quarter
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-19.28M	USD	3 Qtrs
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-48.21M	USD	3 Qtrs
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	-	USD	3 Qtrs
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	-	USD	3 Qtrs
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
Net loss	`ProfitLoss`	$-13.10M	USD	1 Quarter
Net loss	`ProfitLoss`	$-5.46M	USD	1 Quarter
Net loss	`ProfitLoss`	$-48.21M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-19.28M	USD	3 Qtrs
Non-controlling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-20.54K	USD	3 Qtrs
Non-controlling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-20.54K	USD	1 Quarter
Non-controlling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-6.28M	USD	3 Qtrs
Non-controlling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-1.70M	USD	1 Quarter
Net loss attributable to BioSig Technologies, Inc.	`NetIncomeLoss`	$-5.44M	USD	1 Quarter
Net loss attributable to BioSig Technologies, Inc.	`NetIncomeLoss`	$-11.40M	USD	1 Quarter
Net loss attributable to BioSig Technologies, Inc.	`NetIncomeLoss`	$-41.93M	USD	3 Qtrs
Net loss attributable to BioSig Technologies, Inc.	`NetIncomeLoss`	$-19.26M	USD	3 Qtrs
Preferred stock dividend	`DividendsPreferredStock`	$20.29K	USD	3 Qtrs
Preferred stock dividend	`DividendsPreferredStock`	$2.38K	USD	1 Quarter
Preferred stock dividend	`DividendsPreferredStock`	$11.70K	USD	3 Qtrs
Preferred stock dividend	`DividendsPreferredStock`	$4.88K	USD	1 Quarter
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-41.94M	USD	3 Qtrs
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-5.45M	USD	1 Quarter
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-11.40M	USD	1 Quarter
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-19.28M	USD	3 Qtrs
Net loss per common share, basic and diluted (in Dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.38	USD	1 Quarter
Net loss per common share, basic and diluted (in Dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.96	USD	3 Qtrs
Net loss per common share, basic and diluted (in Dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.25	USD	1 Quarter
Net loss per common share, basic and diluted (in Dollars per share)	`EarningsPerShareBasicAndDiluted`	$-1.56	USD	3 Qtrs
Weighted average number of common shares outstanding, basic and diluted (in Shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	29.75M	shares	1 Quarter
Weighted average number of common shares outstanding, basic and diluted (in Shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	21.81M	shares	1 Quarter
Weighted average number of common shares outstanding, basic and diluted (in Shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	26.90M	shares	3 Qtrs
Weighted average number of common shares outstanding, basic and diluted (in Shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	20.12M	shares	3 Qtrs

Cash Flow Statement 76 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-13.10M	USD	1 Quarter
Net loss	`ProfitLoss`	$-5.46M	USD	1 Quarter
Net loss	`ProfitLoss`	$-48.21M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-19.28M	USD	3 Qtrs
Depreciation	`DepreciationDepletionAndAmortization`	$36.42K	USD	3 Qtrs
Depreciation	`DepreciationDepletionAndAmortization`	$18.51K	USD	1 Quarter
Depreciation	`DepreciationDepletionAndAmortization`	$67.09K	USD	3 Qtrs
Depreciation	`DepreciationDepletionAndAmortization`	$23.87K	USD	1 Quarter
Equity based compensation	`AllocatedShareBasedCompensationExpense`	$20.57M	USD	3 Qtrs
Equity based compensation	`AllocatedShareBasedCompensationExpense`	$7.70M	USD	3 Qtrs
Change in fair value of modified options	`OtherNoncashExpense`	-	USD	3 Qtrs
Change in fair value of modified options	`OtherNoncashExpense`	$666.06K	USD	3 Qtrs
Fair value of subsidiary stock issued to acquire research and development from Trek Therapeutics, PBC	`IssuanceOfStockAndWarrantsForServicesOrClaims`	-	USD	3 Qtrs
Fair value of subsidiary stock issued to acquire research and development from Trek Therapeutics, PBC	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$3.17M	USD	3 Qtrs
Fair value of subsidiary stock issued to acquire research and development	`ShareBasedCompensation`	-	USD	3 Qtrs
Fair value of subsidiary stock issued to acquire research and development	`ShareBasedCompensation`	$1.30M	USD	3 Qtrs
Inventory	`IncreaseDecreaseInInventories`	$228.72K	USD	3 Qtrs
Inventory	`IncreaseDecreaseInInventories`	-	USD	3 Qtrs
Vendor deposits	`IncreaseDecreaseInDepositsOutstanding`	$8.83K	USD	3 Qtrs
Vendor deposits	`IncreaseDecreaseInDepositsOutstanding`	$330.44K	USD	3 Qtrs
Prepaid expenses	`IncreaseDecreaseInPrepaidExpense`	$170.39K	USD	3 Qtrs
Prepaid expenses	`IncreaseDecreaseInPrepaidExpense`	$97.16K	USD	3 Qtrs
Security deposit	`IncreaseDecreaseInDepositOtherAssets`	-	USD	3 Qtrs
Security deposit	`IncreaseDecreaseInDepositOtherAssets`	$47.60K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$3.00M	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-226.83K	USD	3 Qtrs
Lease liability, net	`IncreaseDecreaseInOtherOperatingLiabilities`	$-386.00	USD	3 Qtrs
Lease liability, net	`IncreaseDecreaseInOtherOperatingLiabilities`	$4.73K	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-11.58M	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-20.50M	USD	3 Qtrs
Payments of patent costs	`PaymentsToAcquireIntangibleAssets`	-	USD	3 Qtrs
Payments of patent costs	`PaymentsToAcquireIntangibleAssets`	$111.32K	USD	3 Qtrs
Payment of trademark costs	`PaymentsToAcquireOtherProductiveAssets`	$275.00	USD	3 Qtrs
Payment of trademark costs	`PaymentsToAcquireOtherProductiveAssets`	-	USD	3 Qtrs
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$83.30K	USD	3 Qtrs
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$60.14K	USD	3 Qtrs
Net cash used in investing activity	`NetCashProvidedByUsedInInvestingActivities`	$-194.89K	USD	3 Qtrs
Net cash used in investing activity	`NetCashProvidedByUsedInInvestingActivities`	$-60.14K	USD	3 Qtrs
Proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$25.21M	USD	3 Qtrs
Proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$8.62M	USD	3 Qtrs
Proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$9.05M	USD	Point-in-time
Proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$16.16M	USD	Point-in-time
Proceeds from sale of common stock under a At-the-market offering, net of issuance costs	`ProceedsFromOtherEquity`	$1.00M	USD	3 Qtrs
Proceeds from sale of common stock under a At-the-market offering, net of issuance costs	`ProceedsFromOtherEquity`	-	USD	3 Qtrs
Proceeds from sale of subsidiary stock to non-controlling interest, net of issuance costs	`ProceedsFromIssuanceOrSaleOfEquity`	$3.69M	USD	3 Qtrs
Proceeds from sale of subsidiary stock to non-controlling interest, net of issuance costs	`ProceedsFromIssuanceOrSaleOfEquity`	$10.59M	USD	3 Qtrs
Subscription received from subsidiary stock subscription from non-controlling interest	`ProceedsFromMinorityShareholders`	-	USD	3 Qtrs
Subscription received from subsidiary stock subscription from non-controlling interest	`ProceedsFromMinorityShareholders`	$501.00K	USD	3 Qtrs
Proceeds from exercise of options	`ProceedsFromStockOptionsExercised`	$492.53K	USD	1 Quarter
Proceeds from exercise of options	`ProceedsFromStockOptionsExercised`	$20.36K	USD	1 Quarter
Proceeds from exercise of options	`ProceedsFromStockOptionsExercised`	$2.72M	USD	3 Qtrs
Proceeds from exercise of options	`ProceedsFromStockOptionsExercised`	$465.20K	USD	3 Qtrs
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$6.35M	USD	3 Qtrs
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$1.67M	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$41.20M	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$19.63M	USD	3 Qtrs
Net increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$20.64M	USD	3 Qtrs
Net increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$7.86M	USD	3 Qtrs
Cash and cash equivalents, beginning of the period	`CashAndCashEquivalentsAtCarryingValue`	$4.45M	USD	Point-in-time
Cash and cash equivalents, beginning of the period	`CashAndCashEquivalentsAtCarryingValue`	$12.11M	USD	Point-in-time
Cash and cash equivalents, beginning of the period	`CashAndCashEquivalentsAtCarryingValue`	$32.75M	USD	Point-in-time
Cash and cash equivalents, beginning of the period	`CashAndCashEquivalentsAtCarryingValue`	$12.31M	USD	Point-in-time
Cash and cash equivalents, end of the period	`CashAndCashEquivalentsAtCarryingValue`	$4.45M	USD	Point-in-time
Cash and cash equivalents, end of the period	`CashAndCashEquivalentsAtCarryingValue`	$12.11M	USD	Point-in-time
Cash and cash equivalents, end of the period	`CashAndCashEquivalentsAtCarryingValue`	$32.75M	USD	Point-in-time
Cash and cash equivalents, end of the period	`CashAndCashEquivalentsAtCarryingValue`	$12.31M	USD	Point-in-time
Cash paid during the period for interest	`InterestPaidNet`	-	USD	3 Qtrs
Cash paid during the period for interest	`InterestPaidNet`	-	USD	3 Qtrs
Cash paid during the period for income taxes	`IncomeTaxesPaid`	-	USD	3 Qtrs
Cash paid during the period for income taxes	`IncomeTaxesPaid`	-	USD	3 Qtrs
Dividend payable on preferred stock charged to additional paid in capital	`AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings`	$20.29K	USD	3 Qtrs
Dividend payable on preferred stock charged to additional paid in capital	`AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings`	$11.70K	USD	3 Qtrs
Right-to-use assets and lease liability recorded upon adoption of ASC 842	`OtherSignificantNoncashTransactionValueOfConsiderationReceived1`	-	USD	3 Qtrs
Right-to-use assets and lease liability recorded upon adoption of ASC 842	`OtherSignificantNoncashTransactionValueOfConsiderationReceived1`	$422.21K	USD	3 Qtrs
Record right-to-use assets and related lease liability	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	-	USD	3 Qtrs
Record right-to-use assets and related lease liability	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$511.24K	USD	3 Qtrs

Stockholders Equity 59 line items

Line Item	Tag	Value	Unit	Period
Sale of common stock in September 2020 under At-the-market offering, transaction expenses (in Dollars)	`PaymentsOfStockIssuanceCosts`	$182.33B	USD	1 Quarter
Sale of common stock in September 2020 under At-the-market offering, transaction expenses (in Dollars)	`PaymentsOfStockIssuanceCosts`	$182.33B	USD	3 Qtrs
Common stock issued upon exercise of options at an average of per share	`ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisePrice`	$7.57	USD	Point-in-time
Common stock issued upon exercise of options at an average of per share	`ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisePrice`	$4.77	USD	Point-in-time
Common stock issued upon exercise of options at an average of per share	`ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisePrice`	$4.64	USD	Point-in-time
Common stock issued upon exercise of options at an average of per share	`ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisePrice`	$4.66	USD	Point-in-time
Common stock issued upon exercise of options at an average of per share	`ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisePrice`	$10.49	USD	Point-in-time
Common stock issued upon exercise of warrants at an average of per share	`ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1`	$5.00	USD	Point-in-time
Common stock issued upon exercise of warrants at an average of per share	`ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1`	$10.00	USD	Point-in-time
Common stock issued for preferred stock	`PreferredStockRedemptionPricePerShare`	$50.00	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.66M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$9.97M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$29.87M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$12.42M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.32M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$36.01M	USD	Point-in-time
Balance (in Shares)	`CommonStockSharesOutstanding`	30.12M	shares	Point-in-time
Balance (in Shares)	`CommonStockSharesOutstanding`	23.32M	shares	Point-in-time
Sale of common stock	`StockIssuedDuringPeriodValueNewIssues`	$25.21M	USD	3 Qtrs
Sale of common stock	`StockIssuedDuringPeriodValueNewIssues`	$10.69M	USD	Point-in-time
Sale of common stock	`StockIssuedDuringPeriodValueNewIssues`	$8.62M	USD	3 Qtrs
Sale of common stock (in Shares)	`StockIssuedDuringPeriodSharesNewIssues`	2.19M	shares	Point-in-time
Sale of common stock (in Shares)	`StockIssuedDuringPeriodSharesNewIssues`	2.50M	shares	Point-in-time
Sale of common stock (in Shares)	`StockIssuedDuringPeriodSharesNewIssues`	1.07M	shares	Point-in-time
Common stock issued for services	`StockIssuedDuringPeriodValueIssuedForServices`	$1.20M	USD	1 Quarter
Common stock issued for services	`StockIssuedDuringPeriodValueIssuedForServices`	$3.55M	USD	3 Qtrs
Common stock issued for services	`StockIssuedDuringPeriodValueIssuedForServices`	$3.44M	USD	1 Quarter
Common stock issued for services	`StockIssuedDuringPeriodValueIssuedForServices`	$5.80M	USD	3 Qtrs
Common stock issued for services (in Shares)	`StockIssuedDuringPeriodSharesIssuedForServices`	503,038.00	shares	3 Qtrs
Fair value of subsidiary shares issued to acquire research and development	`StockIssuedDuringPeriodValuePurchaseOfAssets`	$1.30M	USD	3 Qtrs
Sale of subsidiary shares to non-controlling interest	`ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesIssuanceOfEquityBySubsidiaryToNoncontrollingInterests`	$10.59M	USD	3 Qtrs
Sale of subsidiary shares to non-controlling interest	`ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesIssuanceOfEquityBySubsidiaryToNoncontrollingInterests`	$3.69M	USD	3 Qtrs
Sale of subsidiary shares to non-controlling interest	`ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesIssuanceOfEquityBySubsidiaryToNoncontrollingInterests`	$3.69M	USD	1 Quarter
Change in fair value of modified options	`AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition`	$666.06K	USD	3 Qtrs
Common stock issued upon exercise of options	`ProceedsFromStockOptionsExercised`	$492.53K	USD	1 Quarter
Common stock issued upon exercise of options	`ProceedsFromStockOptionsExercised`	$20.36K	USD	1 Quarter
Common stock issued upon exercise of options	`ProceedsFromStockOptionsExercised`	$2.72M	USD	3 Qtrs
Common stock issued upon exercise of options	`ProceedsFromStockOptionsExercised`	$465.20K	USD	3 Qtrs
Common stock issued upon exercise of options (in Shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	1.20M	shares	3 Qtrs
Stock based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$1.89M	USD	3 Qtrs
Stock based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$17.02M	USD	3 Qtrs
Stock based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$772.59K	USD	1 Quarter
Stock based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$1.39M	USD	1 Quarter
Preferred Stock dividend	`DividendsPreferredStock`	$4.88K	USD	1 Quarter
Preferred Stock dividend	`DividendsPreferredStock`	$11.70K	USD	3 Qtrs
Preferred Stock dividend	`DividendsPreferredStock`	$2.38K	USD	1 Quarter
Preferred Stock dividend	`DividendsPreferredStock`	$20.29K	USD	3 Qtrs
Net loss	`ProfitLoss`	$-13.10M	USD	1 Quarter
Net loss	`ProfitLoss`	$-5.46M	USD	1 Quarter
Net loss	`ProfitLoss`	$-48.21M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-19.28M	USD	3 Qtrs
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.32M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$12.42M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$36.01M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$9.97M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$29.87M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.66M	USD	Point-in-time
Balance (in Shares)	`CommonStockSharesOutstanding`	30.12M	shares	Point-in-time
Balance (in Shares)	`CommonStockSharesOutstanding`	23.32M	shares	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.